Orano Med
Aurelie Blaise has extensive experience in human resources and program management, currently serving as Resp.RH Programme GAPEXPERT at AREVA since February 2010. Prior to this role, Aurelie worked at AREVA in expertise management from September 2006 to December 2008. Educationally, Aurelie holds a Master's degree in Gestion des Ressources Humaines (Sociologie des Organisations) from Sciences Po, completed in 2007, and a Diplôme d'ingénieur in Génie Mécanique / Matériaux - Innovation Technologique from Université de Technologie de Compiègne (UTC), obtained in 2005.
This person is not in any offices
Orano Med
1 followers
Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope. Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products. For more information please visit www.macrocyclics.com.